TERN Stock Overview
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity.
Notes are coming soon
Terns Pharmaceuticals, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$7.91|
|52 Week High||US$10.67|
|52 Week Low||US$1.45|
|1 Month Change||-16.82%|
|3 Month Change||16.15%|
|1 Year Change||48.68%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-56.99%|
Recent News & Updates
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In GrowthOct 03
Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?Jun 14
Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In GrowthMar 16
We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn RateNov 24
We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash WiselyAug 24
|TERN||US Pharmaceuticals||US Market|
Return vs Industry: TERN exceeded the US Pharmaceuticals industry which returned 5.4% over the past year.
Return vs Market: TERN exceeded the US Market which returned -9.7% over the past year.
|TERN Average Weekly Movement||16.7%|
|Pharmaceuticals Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: TERN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 17% a week.
Volatility Over Time: TERN's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity.
Terns Pharmaceuticals, Inc. Fundamentals Summary
|TERN fundamental statistics|
Is TERN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TERN income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.19|
|Net Profit Margin||-5,877.10%|
How did TERN perform over the long term?See historical performance and comparison